Catalyst Pharmaceuticals
Nil Patel is a Senior Manager in Regulatory Affairs with a wealth of experience in various roles at companies like Catalyst Pharmaceuticals, Inc., UCB, and American Regent, Inc. Nil also has a background in research and quality assurance, with internships at organizations like MP Biomedicals and Nationwide Children's Hospital. Nil holds a Master of Clinical Research in Regulatory Affairs and a Bachelor of Science in Neuroscience from The Ohio State University.
This person is not in any offices
Catalyst Pharmaceuticals
2 followers
Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.